Harry H. Yoon, MD, MHS, discusses tislelizumab and platinum-containing chemotherapy in unresectable or metastatic esophageal squamous cell carcinoma whose tumors express PD-L1 at a level of 1 or ...

Immutep Limited (ASX: IMM; NASDAQ: IMMP) (“Immutep” or “the Company”), a late-stage immunotherapy company targeting cancer ...

The greater the number of risk factors in patients with cutaneous squamous cell carcinoma, the higher the likelihood of poor ...

Completed strategic review to focus on oncology and liver diseases with the acquisition of global rights to GB3226 (formerly BRM-1420), a dual ...

As of December 31, 2024, Pyxis Oncology had cash and cash equivalents, including restricted cash, and short-term investments, of $128.4 million. The Company believes that its current cash, cash ...

Reports FY24 revenue $16.146M, consensus $13.8M. “We are committed to the development of a novel therapy for patients with recurrent or ...

A collaborative research team from The University of Hong Kong (HKU) and West China Hospital of Sichuan University has made a ...

Dogs that have oral squamous cell carcinomas often need surgery that disfigures their jaws and lower their quality of ...

Skin cancer is the most common cancer in the U.S., with risks influenced by factors like sun exposure, skin type, and income.

Journal of the American Medical Association study provides further evidence that Multikine can treat unmet need in ~70% of ...

We recently published a list of 12 Best Multibagger Stocks to Buy in 2025. In this article, we are going to take a look at ...

Researchers conducting a clinical trial of immunotherapy drugs for people with head and neck squamous cell carcinomas (HNSCCs ...